2 results match your criteria: "University of Otago PO Box 4345[Affiliation]"
Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease.
Curr Opin Pharmacol
December 2020
Department of Clinical Pharmacology, Christchurch Hospital, 2 Riccarton Avenue, Christchurch 8011, New Zealand; Department of Gastroenterology, Christchurch Hospital, 2 Riccarton Avenue, Christchurch 8011, New Zealand; Christchurch Campus, School of Medicine, University of Otago PO Box 4345, Christchurch 8140, New Zealand. Electronic address:
Inflammatory bowel disease (IBD) is increasingly common, and results in significant morbidity. Traditional therapies include corticosteroids, aminosalicylates, thiopurines and methotrexate but in more recent years biologics have transformed the management of IBD. However, these agents come with a significant financial cost, making them unavailable for many patients worldwide.
View Article and Find Full Text PDFUnrecognised and unmet physical health problems in a national cohort of very low birthweight young adults and controls.
J Prim Health Care
April 2019
Christchurch Health and Development Study, University of Otago, Christchurch, New Zealand.
INTRODUCTION Young adults are often reluctant to seek medical attention. Compared with full-term controls, very low birthweight (<1500 g; VLBW) young adults may have more health problems. AIM To assess the frequency of unrecognised or unmet physical health needs during a comprehensive health and welfare assessment of a national cohort of VLBW adults born in 1986 compared with full-term controls.
View Article and Find Full Text PDF